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QALY, which indicated that Nilotinib is an advantageous treatment for CML pa-
tients in regards to treatment efficacy and cost effectiveness. One-way sensitivity
analyses indicated the results to be robust.CONCLUSIONS: Based on awillingness-
to-pay threshold of $120-$150,000/QALY, Nilotinib treatment in CML patients who
were resistant or intolerant to Imatinib is a cost-effective treatment. The results,
however, may be less applicable to high-risk patients, the elderly, children and
those eligible for bone marrow transplantation.
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OBJECTIVES: Anti-angiogenic therapy has become an integral component of treat-
ment for metastatic colorectal cancer patients. During last 10 years several studies
were conducted to test the safety and efficacy of anti-angiogenic therapies inmCRC
patients. This study reviewed the results of randomized controlled trials published
in peer-reviewed journals. METHODS: We searched the MEDLINE, and abstracts
from ECCO, ESMO and ASCO until May 2011. Studies were selected for randomized
controlled trials on targeted anti-angiogenic drugs in mCRC. Primary endpoints
reviewed were progression-free (PFS) and overall survival (OS). Response rates,
toxicity and secondary resectability were secondary endpoints. Aggregated data
were further analyzed to understand comparative safety and efficacy. RESULTS:
Until May 2011, eligible mCRC randomized clinical trials for this reviewwere avail-
able for bevacizumab (5 trials including 3101 patients) and vatalanib (2 trial includ-
ing 2033 patients). Overall, anti-angiogensis therapy formCRC shows significantOS
and PFS benefit versus comparators. The median OS and PFS benefit for regimens
containing Bevacizumab were 3 and 3.15 months, versus background chemother-
apy. The median OS and PFS benefit for vatalanib containing regimens were sta-
tistically insignificant versus background chemotherapy. CONCLUSIONS: Anti-an-
giogensis therapy with Bevacizumab for mCRC shows significant OS and PFS
benefit versus comparators.
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OBJECTIVES: The main objective of this study was to analyze the treatment pat-
terns in patients with advanced NSCLC treatment in a regional community setting:
The Georgia Cancer Specialists Network.METHODS: Patients were included in the
study if they were newly diagnosed with NSCLC as of the first practice visit and
diagnosed with stage III or stage IV disease between January 1, 2005 and June 2010.
Patients treated with chemotherapy were followed from initial NSCLC diagnosis
until death, end of study period or lost to follow up. The network’s Electronic
Medical Record (EMR)was used to identify chemotherapy agents and sequencing of
therapy. RESULTS: A total of 291 patients were identified with advanced NSCLC
(Stage IIIB or IV). Patients ranged in the age of 40 to 85 years with 125 females and
166 males. Of the 291 patients who received first line therapy, 122 (41.9%) were
treated with Carboplatin/Paclitaxel, 45 (15.5%) with Carboplatin/Paclitaxel/Bevaci-
zumab, 24 (8.2%) with Paclitaxel and 19 (6.5%) with Bevacizumab. Of the 125 pa-
tients who received second line therapy, 52(17.9%) were treated with Pemetrexed,
13 (4.5%)withDocetaxel and 8(2.7%)with Carboplatin/Gemcitabine. Themost com-
mon therapies used in the 40 patients who received third line were Pemetrexed
with 11 patients (3.8%), Docetaxel with 10 patients (3.4%), Gemcitabine with 4 pa-
tients (1.4%) andVinorelbinewith 3 patients (1%).CONCLUSIONS:Of these patients
with advanced NSCLC, 13.7% received third line therapy after previous treatment
with first and second line therapies. The majority of the agents prescribed follow
NCCN guidelines. In the third line the wide variation suggests a lack of standard of
care. Additional rigorous clinical effectiveness trials of drugs in third line treatment
are warranted to understand the benefit in NSCLC patients.
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BACKGROUND: Multiple myeloma (MM) is a B cell malignancy, of fully differenti-
ated plasma cells, and is the second most prevalent hematological malignancy
(10%) after non-Hodgkin’s lymphoma. Despite recent advances in the treatment
options for patientswithMM, it remains incurable and the vastmajority of patients
will relapse or become refractory to treatment. To date there is little information on
real world treatment outcomes for many of existing regimens. OBJECTIVES: The
objective of this multi-center observational study is to assess treatment outcomes
of patients with relapsed or refractory MM receiving either single or combination
novel therapies in real-world clinical practice. METHODS: This is a prospective,
non-interventional, cohort study that includes patients with relapsed or refractory
MM who will receive treatment for MM between 2012 and 2018 in North America
and Europe. In order to reflect real-world clinical practice patterns, patients cur-
rently enrolled in clinical trials are not eligible for this study. Patients will be fol-
lowed for up to three years, until death, enrollment in an investigational trial, or
withdrawal of consent, whichever comes first. The primary endpoints of this real
world study, include disease progression/response, progression-free survival (PFS),
overall survival (OS), secondary malignancy, and occurrence of adverse events.
Data on patient demographics, clinical characteristics, treatment patterns, health
care resources utilization, and patient-reported outcomes (e.g., EQ-5D) will also be
collected by using electronic case report throughout the study. The potential asso-
ciation between PFS and OS in this patient population will be also assessed. The
anticipated study population across multiple geographic regions is approximately
1000 patients. RESULTS: Findings from this prospective, non-interventional, mul-
tiregional studywill contribute to the knowledge of treatment patterns for relapsed
or refractory MM in real-world clinical practice.
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OBJECTIVES: Prostate cancer represents the 2nd most common cause of cancer
mortality[1]. Clinical studies showed that chemotherapy (CT) had survival benefits
for Metastatic CRPC[2-6]. This study described 1st-line and 2nd-line CT and investi-
gated OS benefits of 2nd line CT using a real-world data. METHODS: The Georgia
Cancer Specialist Database containing CT,medical and pharmacy information, and
lab results for patients (PTs) with cancer (2005-2011) was used. PTs greater than 18
years old with initial stage IV CRPC who received one type CT protocol (PL), as
first-line group, and two types of PLs, as second-line group, were followed from the
first administration of CT (index date, ID) to the earlier of death or loss to follow-up.
CT use was described. Kaplan-Meier survival curve was compared between first-
line and second-line groups using log-rank test. The impact of second-line CT on
OS was further examined using multivariate Cox model with adjustment of PTs’
baseline age, race, Charlson Comorbidity Index (CCI), bisphosphonate use, and
ECOGperformance scores. RESULTS:The study included 124 PTs, with 86 (69.4%) as
first-line PTs, range in age from 18-90 (median 74 years of age), 52.4% of raceWhite,
32.3% African American, and 15.3% other or unknown race, average weight was
185LB (ranging 100-365LB), average baseline PSA 731 ng/ml (ranging 0.05-21,743ng/
ml), 107(86.3%) PTs with one or more CCI comorbid conditions, 10 (8.1%) PTs with
ECOG score as 3 or 4. 96 (77.4%). Docetaxel was used as first-line CT. Other first-line
CT drugs were: Denosumab, vinorelbine, sipuleucel-T,mitoxantrone/Prednisone,
and Cisplatin. Second-line CT drugs were: denosumab, Novantrone/Prednisone,
Cabazitaxel, and Carboplatin. Median survival was 17 months for all, 14 and 19
months for first-line and second-line PTs, respectively (P0.0654). Multivariate
COX model found a higher survival for second-line PTs (HR0.361, P0.010).
CONCLUSIONS: This study suggested that second-line CT was associated with
prolonged OS in metastatic CRPC.
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OBJECTIVES: To assess the clinical and economic burden of breast cancer patients
in the US veteran population. METHODS: A retrospective study of patients diag-
nosed with breast cancer between October 1, 2005 and September 30, 2010 was
conducted using the Veterans Health Affairs Medical SAS Datasets. Health care
resource utilization and costs were assessed in the 12-month follow-up period.
Patients’ demographic, clinical and discharge statuses were compared using Chi-
square testing and standardized differences. Mortality and survival rates were
calculated using the Kaplan and Meier method and the PROC LIFETEST procedure.
RESULTS: In patients identified with breast cancer (n11,719), the total mortality
rates in the 12-month follow-up period were 17.04% (n1,993), with 26.07%
(n1,192) for patients age 65 and over, 10.64% for age 40 to 64, and 20.22% (n90) for
patients under age 39. The medications most commonly prescribed 1 year after
breast cancer diagnosis were sodium chloride (2.43%), anastrozole (1.61%), tamox-
ifen (1.23%), dextrose (1.15%) and hydrochlorothiazide (1.07%). The most com-
monly prescribed laboratory tests were for glucose quant (3.99%), sodium (3.88%),
potassium (3.81%), creatinine (3.75%), and chloride (3.73%). The percentage of pa-
tientswho had follow-up inpatient visitswas 19.00%,which translated into $22,220
in inpatient costs per patient, while the percentage of patients who had follow-up
emergency room (ER) visits was 18.79%, which translated into $140.53 ER costs per
patient. CONCLUSIONS: The risk of developing breast cancer increases with age.
The mortality rate is relatively low for US veteran breast cancer patients between
the ages of 40 and 64, but more than doubles for patients over age 65.
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